BioSpace’s Post

Thoughts on this? >> Kyverna Therapeutics' CAR-T cell therapy shows promise against autoimmune diseases - BioPharma-Reporter.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #pharma #biotech

Thoughts on this? >> Kyverna Therapeutics' CAR-T cell therapy shows promise against autoimmune diseases - BioPharma-Reporter.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #biotech #pharmaceutical #pharma

🔬 Exciting Advances in CAR-T Therapy for Multiple Myeloma! 🔬 Poseida Therapeutics unveils promising Phase I findings for its BCMA-targeting allogeneic CAR-T candidate, P-BCMA-ALLO1, at the 65th Annual Meeting & Exposition of the American Society of Hematology. The study reveals an impressive 82% overall response rate, with a 100% response rate in patients previously treated with autologous CAR-T BCMA-targeted therapy. Notably, the conditioning regimen with cyclophosphamide significantly influences CAR-T cell expansion and persistence. These groundbreaking results support the efficacy of P-BCMA-ALLO1, offering hope for relapsed/refractory multiple myeloma patients. 🩸💪 #CAR-TTherapy #CancerResearch #MedicalAdvancements

The global Natural Killer Cells Therapeutics market was valued at US$ 350 million in 2023 and is anticipated to reach US$ 1012.3 million by 2030 witnessing a CAGR of 16.4% during the forecast period 20242030. #GlobalNKCellTherapeutics #NKCellTherapies #NKCellDirectedAntibodies #CancerTreatment #GastrointestinalDiseases #ImmunoproliferativeDisorders #MarketGrowth #MedicalResearch #InnovativeTherapies #ImmuneSystem

Advances in CAR T-Cell Therapy and Bispecifics for Relapse/Refractory Multiple Myeloma: Insights From ESMO Congress 2024: The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development. #finance #pharmacy #lifesciences

Points of interest 1.     The second-generation radio-pharmaceutical/theranostics agents are more targeted with higher radiation ‘payload’. That makes them better than 1st generation. This includes alpha (Xofigo with Radium-223 as radioactive agent) beta emitters (Pluvicto with Lutetium as radioactive agent). 2.     Better, diagnostic, and therapeutic combinations –PET/CT (PSMA or DOTATATE) scan as diagnostic agent assessing avidity and disease burden, followed by Lu-PSMA/LuTate therapy as therapeutic agent – ‘see and treat’ approach. 3.     Nearly tripling of transaction in this space – (9 in 2021, increasing to 25 in 2022). 4.     Deals spread over diagnostic (~41%), theranostics (~32%) and therapeutics (~27%). 5.     17 deals with – Pre-clinical deals worth $834 million, diagnostics assets $ 34 million, theranostics $ 729 million and therapeutics $ 1026 million. 6.     More pre-clinical deals hopefully mean more licensing and M&A activity. https://lnkd.in/gSFCMMhi

Thoughts on this? >> Second-Generation NK Cell Engager Heading to Trial for CD33+ Leukemia - CGTLive™ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #biotech #healthcare #pharmaceutical

Oricell Therapeutics announced that the U.S. FDA has granted Fast Track Designation for OriCAR-017, a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). This designation is expected to accelerate the progress of clinical trials and the New Drug Application (NDA/BLA) review process. Prior to this, the FDA has granted Orphan Drug Designation (ODD) and has cleared an Investigational New Drug Application (IND) for OriCAR-017. As a groundbreaking innovation leveraging Oricell Therapeutics' cutting-edge proprietary technology platforms, OriCAR-017 exhibits clearly differentiated binding avidity, persistence, anti-tumor efficacy, and safety profile. #OriCAR017 #FastTrackDesignation #FDAApproval #CAR_TCellTherapy #GPRC5D #MultipleMyeloma #InnovativeTherapies #ClinicalTrials #NewDrugApplication #OrphanDrugDesignation #BiotechInnovation #CancerResearch #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gvsPdeVM

Innate secures speedy resolution of FDA hold on lymphoma trials ahead of key regulatory talks >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #competitivemarketing #biotech #healthcare

The first-in-human trial will evaluate STX-001, which uses synthetic self-replicating mRNA technology to express the interleukin-12 (IL-12) cytokine within the tumour microenvironment for longer periods. Strand Therapeutics https://lnkd.in/dvXQ_Cb2